Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

Humana Inc Add to portfolio

INX:HUM, Feb 27, 10:51 UTC

Latest INX:HUM News

Filter your feed

Apply Filter

Wednesday, February 05


News

Macy's, Humana rise; Merck, Ford Motor fall

F HUM +1 more F HUM MRK

The financial services company raised its dividend after reporting surprisingly good fourth-quarter profit. Ford Motor Co., down 87 cents at $8.31. Wolves Wolves trade Covington, four others as part of four-team, 12-player deal. Twins One wild night, two big trades: What it all means for Twins and Wolves. Twins Graterol to Boston, Maeda to Twins in blockbuster deal sending Mookie Betts to L.A. National Not Guilty: Split Senate acquits Trump of impeachment.

Read Full Details

Topics:
  • Business
  • Financial
News

Health insurer Humana's fourth-quarter profit rises 44%

HUM TRI

Health insurer Humana's fourth-quarter profit rises 44% | NASDAQ. Feb 5 (Reuters) - U.S. health insurer Humana Inc reported a 44% rise in fourth-quarter profit on Wednesday, helped by higher revenue from its Medicare business. The company's net income rose to $512 million, or $3.84 per share, in the quarter ended Dec. 31, from $355 million, or $2.58 per share, a year earlier. (Reporting by Manojna Maddipatla and Tamara Mathias in Bengaluru Editing by Saumyadeb Chakrabarty) ((manojna.kalyani@thomsonreuters.com; +91 8061822700)) Keywords: HUMANA RESULTS/ (URGENT).

Read Full Details

Topics:
  • Business
  • Financial

Tuesday, February 04


News

The Zacks Analyst Blog Highlights: Amazon.com, Procter & Gamble, Pfizer, Southwest Airlines and Humana

HUM AMZN +3 more HUM AMZN PG PFE LUV

Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Looking at Q4 as a whole, combining the actual results that have come out with estimates for the still-to-come companies, total earnings are expected to be down -0.6% from the same period last year on +4% higher revenues. The Zacks analyst believes that the company’s solid second-quarter fiscal 2020 earnings mark the continuation of its positive surprise trend. Pfizer’s shares have underperformed the Zacks Large Cap Pharmaceuticals over the past two-year period (+7.4% vs. +17.9%). But the Zacks analyst believes that the company’s Consumer Healthcare joint venture with Glaxo, the Array acquisition and the pending merger of Upjohn unit with Mylan, if successful, will make Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.

Read Full Details

Topics:
  • Business
  • Financial

Wednesday, January 22


News

Should Value Investors Pick Humana (HUM) Stock Right Now?

HUM

After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value? Let’s put, Humana, Inc. HUM stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. This level actually compares pretty favorably with the market at large, as the PE for the S&P 500 compares in at about 20.83. If we focus on the stock’s long-term PE trend, the current level Humana puts current PE ratio below its midpoint (which is 22.38) over the past five years.

Read Full Details

Topics:
  • Business
  • Financial

Wednesday, January 15


News

Zacks.com featured highlights include: Calavo Growers, BMC Stock, Humana, Vipshop and AllianceBernstein

HUM

Naturally, fears of a correction are understandable. Since market watchers are still predicting decent gains in equities in 2020, it would be wise to bet on quality stocks right now. Investors can follow the ROE trend in companies and compare this to historical or industry benchmarks to pick a winning stock. However, stepping beyond the basic ROE and analyzing it at an advanced level could lead to even better returns. It can help investors to segregate companies with higher margins from those having a high turnover. For example, high-end fashion brands generally survive on high margins compared with retail goods, which rely on a higher turnover. And one of the ROE components – equity multiplier (explained below) – can help you judge how burdened a company is with debts. Screening tools like Zacks Research Wizard can come to your rescue and help you shortlist stocks that look impressive with a DuPont analysis. For the rest of this Screen of the Week article please visit Zacks.com at:https://www.zacks.com/stock/news/716990/5-top-ranked-dupont-confirmed-quality-stocks.

Read Full Details

Topics:
  • Business
  • Financial

Friday, December 27


News

Humana (HUM) Grows on Strong Medicare Business Expansion

HUM

Humana Inc. HUM is well-poised for growth on the back of its robust Medicare business. The company recently announced the launch of Humana Honor Medicare Advantage plans for 2020, designed to complement the Veterans Affairs program.Earlier, management stated that it plans to add 270,000-330,000 members to its Medicare Advantage plans for individuals in 2020. As of Sep 30, 2019, the company had more than 2.3 million individual Medicare Advantage members.Other companies in the same space like Anthem, Inc. ANTM has also been working on its Medicare Advantage network. Also, Centene Corporation CNC is on course to acquire WellCare Health Plans, Inc. WCG, which is expected to close by the first half of 2020. This combined entity will have a wider scale and diversification with more than 12 million Medicaid and nearly 5 million Medicare members.Shares of this Zacks Rank #3 (Hold) company have surged 30.9%, outperforming its industry's rally of 20.5%.

Read Full Details

Topics:
  • Business
  • Financial

Tuesday, December 17


News

Humana (HUM) to Take Over Enclara for Enriched Healthcare

HUM

Expected to close in the first half of 2020, the deal will likely have an immaterial impact on 2020 earnings. However, financial terms of the transaction were not disclosed.A Few Details About EnclaraEnclara, one of the nation’s largest hospice pharmacy and benefit management providers, aims at easing care delivery for patients resorting to complex care. The transaction includes the acquisition of Enclara Pharmacia, GuidantRx and Avanti Health Care Services and is subject to certain closing conditions.Rationale Behind the DealWith this strategic move, Humana would be able to enhance its wide-ranging care package to serve pharmacy-based requirements associated with hospice care. Additionally, the company would also be able to simplify the mail order pharmacy experience and upgrade its technology stack for in-house pharmacy via better mobile medication management and electronic medical record (EMR) connectivity.Humana looks forward to utilizing Enclara’s clinical management expertise and its trusted relationship with customers that it has built over the past 20 years. The move is in line with its commitment to provide enriched healthcare to individuals.Moreover, the deal would allow it to boost its PBM game, which is necessary as other insurers are also putting in concentrated efforts to solidify their presence in the pharmacy benefit management space. For example, Anthem, Inc. ANTM launched its own PBM, IngenioRx.Other Significant AcquisitionsAcquisitions have always been the company’s major growth trajectory. Some most significant ones are the purchase of Family Physicians Group, Your Home Advantage, Curo and a share in Kindred at Home, which helped the company deepen its toes in the home health and hospice market.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Monday, December 16


News

Humana to purchase hospice PBM Enclara Healthcare

HUM

The deal, the terms of which were not disclosed, comes as other insurers are ramping up efforts to boost their presence in the pharmacy benefit management space. Humana said in a release when announcing the deal on Monday that it enables the insurer to cover pharmacy-related needs for hospice care patients and advance technology for in-home pharmacy through improved electronic medical record connectivity. “Enclara represents a logical extension of Humana Pharmacy’s strategy given the company’s unique ability to play a role in advanced illness care and supplement our existing care delivery system,” said Scott Greenwell, president of Humana’s PBM arm Humana Pharmacy Solutions, in a statement. UnitedHealth Group's Optum, home to its PBM arm OptumRx, is a significant source of financial growth for the healthcare giant.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

Humana to acquire hospice pharmacy, PBM Enclara

HUM

The buy of the private, for-profit Enclara is meant to bolster Humana's offerings for the elderly, a population that accounts for a disproportionate share of the country's healthcare costs. Humana hopes the addition of Enclara will allow it to streamline its mail-order pharmacy and build out its offerings for in-home pharmacy through technology like enhanced mobile medication management and EHR connectivity, the company said. "Enclara represents a logical extension of Humana Pharmacy's strategy given the company's unique ability to play a role in advanced illness care and supplement our existing care delivery system," Scott Greenwell, president of Humana Pharmacy Solutions, said in a statement. Humana's last acquisition also focused on the hospice space, following the $14.1 billion snap-up of Kindred Healthcare, a home health, hospice and community care provider in July last year.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Monday, December 09


News

Oakmark's Bill Nygren Adds Humana, DXC Technology to Portfolio

HUM

According to the fund's fact sheet, he prefers to take a position when the stock is trading at a substantial discount to his estimate of intrinsic value, then waits for the gap between the two to close before selling. The Louisville, Kentucky-based health insurance company has a $45.77 billion market cap; its shares were trading around $345.63 on Monday with a price-earnings ratio of 18.38, a price-book ratio of 3.94 and a price-sales ratio of 0.76. The company's profitability scored an 8 out of 10 rating on the back of strong margins and returns that outperform over half of its competitors. As a result of recording consistent earnings and revenue growth, Humana also has a business predictability rank of 4.5 out of five stars. Larry Robbins (Trades, Portfolio), Steve Mandel (Trades, Portfolio), the Vanguard Health Care Fund (Trades, Portfolio), Lee Ainslie (Trades, Portfolio), Diamond Hill Capital (Trades, Portfolio), Pioneer Investments (Trades, Portfolio), Steven Cohen (Trades, Portfolio), Chris Davis (Trades, Portfolio), Joel Greenblatt (Trades, Portfolio), David Tepper (Trades, Portfolio), Paul Tudor Jones (Trades, Portfolio), Caxton Associates (Trades, Portfolio), First Pacific Advisors (Trades, Portfolio) and Ron Baron (Trades, Portfolio) are also shareholders.

Read Full Details

Topics:
  • Business
  • Financial